Traders sold shares of Relypsa Inc. (NASDAQ:RLYP) on strength during trading hours on Thursday. $116.62 million flowed into the stock on the tick-up and $162.36 million flowed out of the stock on the tick-down, for a money net flow of $45.74 million out of the stock. Of all stocks tracked, Relypsa had the 0th highest net out-flow for the day. Relypsa traded up $11.85 for the day and closed at $31.95

A number of equities analysts have issued reports on the company. Brean Capital reiterated a “buy” rating and set a $26.00 price target on shares of Relypsa in a research report on Sunday, April 17th. Mizuho reiterated a “hold” rating on shares of Relypsa in a research report on Sunday, April 17th. BTIG Research reiterated a “buy” rating and set a $45.00 price target on shares of Relypsa in a research report on Sunday, April 17th. Cowen and Company reiterated a “buy” rating on shares of Relypsa in a research report on Sunday, May 29th. Finally, Morgan Stanley reiterated a “hold” rating on shares of Relypsa in a research report on Sunday, May 29th. Seven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Relypsa has a consensus rating of “Buy” and an average target price of $36.68.

The firm’s market capitalization is $1.44 billion. The stock has a 50 day moving average of $19.70 and a 200-day moving average of $17.66.

Relypsa (NASDAQ:RLYP) last released its earnings results on Wednesday, May 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.46) by $0.20. The business had revenue of $12.40 million for the quarter, compared to analyst estimates of $6.88 million. During the same quarter in the previous year, the firm posted ($0.78) EPS. Equities analysts expect that Relypsa Inc. will post ($5.95) EPS for the current year.

A number of institutional investors have added to or reduced their stakes in RLYP. Ashburton Jersey Ltd acquired a new position in Relypsa during the fourth quarter valued at about $1,725,000. Royce & Associates LLC boosted its position in Relypsa by 34.6% in the fourth quarter. Royce & Associates LLC now owns 407,700 shares of the company’s stock valued at $11,554,000 after buying an additional 104,700 shares during the last quarter. ProShare Advisors LLC boosted its position in Relypsa by 9.9% in the fourth quarter. ProShare Advisors LLC now owns 38,272 shares of the company’s stock valued at $1,085,000 after buying an additional 3,445 shares during the last quarter. California Public Employees Retirement System acquired a new position in Relypsa during the fourth quarter valued at about $3,826,000. Finally, California State Teachers Retirement System boosted its position in Relypsa by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 60,422 shares of the company’s stock valued at $1,712,000 after buying an additional 1,084 shares during the last quarter.

Relypsa, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of polymer-based drugs to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patients’ lives and even be life-threatening. The Company’s first drug candidate is Veltassa (patiromer) for oral suspension, or Veltassa, for the treatment of hyperkalemia.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.